leadf
logo-loader
AIM:C4XD FRA:C4J

C4X Discovery Holdings PLC

Receive alerts
Market:
AIM
Market Cap:
£71.08 m
Price
31.20 GBX
Change
-4.00%
52 weeks high
54.50
52 weeks low
10.10

In brief

C4XD is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, developed by partners for the benefit of patients.  It’s commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners. The company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals.

In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.

In 2021, C4XD signed an exclusive worldwide licensing agreement with Sanofi worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme. 

Snapshot

  • C4X Discovery focuses on expanding portfolio as it sits on comfortable cash pile
  • C4X Discovery happy in the pre-clinical world as partner list grows
  • C4X Discovery announce 'sizeable deal and one we're very proud of' with Sanofi worth up to €414mln